* X4 Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on August 8 for the period ending June 30 2024
* The Boston Massachusetts-based company is expected to report revenue of $278.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for earnings of 1 cent per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $5.00, above its last closing price of $0.61.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.15 -0.16 -0.26 Missed -59.6
Dec. 31 2024 -0.17 -0.15 -0.10 Beat 34.6
Sep. 30 2023 -0.15 -0.01 93.3
Jun. 30 2023 -0.16 -0.16 -0.33 Missed -102
Mar. -0.21 -0.22 -0.16 Beat 26.3
31 2023
Dec. 31 2022 -0.21 -0.24 -0.29 Missed -20.2
Sep. 30 2022 -0.31 -0.30 -0.26 Beat 13.1
Jun. 30 2022 -0.65 -0.64 -0.60 Beat 6
This summary was machine generated August 6 at 17:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments